Spravato has been approved since 2019 for TRD, with its label extended the following year as a rescue therapy for adults with major depressive disorder (MDD) who were at risk of self-harm or suicide.

Vanessa Kanu Kanu; Executive Vice President and Chief Financial Officer; Aptargroup Inc Ladies and gentlemen, thank you for standing by. Welcome to Aptar 2024 fourth quarter and annual results ...

Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body. The Institute for Clinical ...

To help, we've collected our favorite “I love you” quotes from the likes of William Shakespeare, Ernest Hemingway, Maya Angelou, Emily Dickinson and a host of poets and writers whose eloquence ...

- A single dose of BPL-003, combined with relapse prevention therapy, produced meaningful and sustained reductions in alcohol use, with 50% of patients maintaining complete abstinence out to three ...